Screener
Tarsus Pharmaceuticals, Inc. TARS PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 561,989 | 522,782 |
| Restricted cash, non-current | 2,001 | 2,002 |
| Inventory, non-current | 2,525 | 2,532 |
| Property and equipment, net | 20,489 | 11,665 |
| Intangible assets, net | 6,885 | 7,366 |
| Operating lease right-of-use assets | 9,911 | 10,080 |
| Long-term investments | 6,682 | 3,870 |
| Other assets | 660 | 1,861 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s PP&E (net)?
- Tarsus Pharmaceuticals, Inc. (TARS) reported PP&E (net) of $20.49M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s PP&E (net) changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s PP&E (net) increased by 543.9% year-over-year, from $3.18M to $20.49M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s PP&E (net)?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s PP&E (net) has grown at a 84.3% compound annual growth rate (CAGR), from $548K to $11.67M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude